Dementia is a syndrome of cognitive impairment that affects memory, cognitive abilities and behaviour, and significantly interferes with a person’s ability to perform daily activities. In 2020, its global estimated prevalence was over 50 million. This comprises 13 million in Europe, which will reach 15 million in 2030. This neurodegenerative condition has a complex pathogenesis and pathology, and effective therapies that delay or stop its progression are still lacking. Genetics and known modifiable risk factors account for around 7% and 40% of global dementia, respectively while the remaining large proportion is attributable to unknown risk factors. Interestingly, emerging evidence has implicated the gut microbiome as one of the important determinants of the occurrence of dementia. While epidemiological investigations have widely reported associations between the composition and the diversity of the gut microbiome with the risk of dementia, the relationship of the gut microbiome function, particularly the gut microbiome-derived metabolites with the risk of dementia remains largely underexplored. In addition, it is well known that inflammatory processes underlie the pathogenesis of dementia. Therefore, it is likely that there could be an intricate interplay between the gut microbiome-derived metabolites and systemic inflammation in the development of dementia. This presentation provides a background on this and how we intend to bridge this knowledge gap through an epidemiological investigation of the relationship of circulating gut microbiome-derived metabolites and systemic inflammation with the risk of dementia.
Online (Zoom): Meeting-ID: 632 6761 6902 - Code: 375292